Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HDM-SPIRE for house dust mite-induced rhinoconjunctivitis
NL-OMON42005Phase 2Not yet recruiting
- Sponsor
- NIOX Group
- Start
- Dec 2014
- Modality
- Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of HDM-SPIRE in allergic rhinoconjunctivitis (ARC), house dust mite allergy, sponsored by NIOX Group. Planned start Dec 2014; status: not yet recruiting.
02
Drugs
HDM-SPIRE
03
Conditions
allergic rhinoconjunctivitis (ARC)house dust mite allergy
Beyond the preview
Go deeper on NL-OMON42005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42005.